Status:
COMPLETED
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Lung Cancer (NSCLC)
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the life of patients with squamous only non small cell lung cancer more than placebo plus Paclit...
Eligibility Criteria
Inclusion
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
- Subjects with NSCLC of predominantly squamous histology documented by histology or cytology from brushing, washing or needle aspiration of a defined lesion but not from sputum cytology alone
- Stage IV or Recurrent NSCLC (per the 7th International Association for the Study of Lung Cancer (IASLC) classification)
- At least 1 measurable tumor lesion, as defined by mWHO criteria, that is not located in a previously irradiated area
- Eastern Cooperative Oncology Group (ECOG) performance status ≤1
Exclusion
- Brain metastases
- Malignant pleural effusion that is recurrent
- Documented history of severe autoimmune or immune mediated symptomatic disease that required prolonged (more than 2 months) systemic immunosuppressive (ie, steroids) treatment
Key Trial Info
Start Date :
October 13 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 3 2018
Estimated Enrollment :
342 Patients enrolled
Trial Details
Trial ID
NCT02279732
Start Date
October 13 2014
End Date
May 3 2018
Last Update
August 28 2019
Active Locations (49)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Beijing, Beijing Municipality, China, 100032
2
Local Institution
Beijing, Beijing Municipality, China, 100042
3
Local Institution
Chongqing, Chongqing Municipality, China, 400042
4
Local Institution
Fuzhou, Fujian, China, 350025